Competing risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malaria: A WorldWide Antimalarial Resistance Network individual participant data meta-analysis

P Dahal; JA Simpson; S Abdulla; J Achan; I Adam; A Agarwal; R Allan; AR Anvikar; E Arinaitwe; EA Ashley; GR Awab; Q Bassat; A Björkman; F Bompart; S Borrmann; T Bousema; I Broek; H Bukirwa; VI Carrara; M Corsi; M Cot; U D'Alessandro; TME Davis; M De Wit; P Deloron; M Desai; PR Dimbu; D Djalle; A Djimde; G Dorsey; OK Doumbo; CJ Drakeley; S Duparc; MD Edstein; E Espie; A Faiz; C Falade; C Fanello; JF Faucher; B Faye; F De Jesus Fortes; NB Gadalla; O Gaye; JP Gil; B Greenwood; A Grivoyannis; K Hamed; TT Hien; D Hughes; G Humphreys; J Hwang; ML Ibrahim; B Janssens; V Jullien; E Juma; E Kamugisha; C Karema; HA Karunajeewa; JR Kiechel; F Kironde; PE Kofoed; PG Kremsner; V Lameyre; SJ Lee; K Marsh; A Mårtensson; M Mayxay; H Menan; P Mens; TK Mutabingwa; JL Ndiaye; BE Ngasala; H Noedl; F Nosten; AT Offianan; M Oguike; BR Ogutu; P Olliaro; JB Ouedraogo; P Piola; CV Plowe; MM Plucinski; OJ Pratt; Z Premji; M Ramharter; C Rogier; L Rombo; PJ Rosenthal; P Sawa; B Schramm; C Sibley; V Sinou; S Sirima; F Smithuis; SG Staedke; I Sutanto; AO Talisuna; J Tarning; WRJ Taylor; E Temu

Journal article

Competing risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malaria: A WorldWide Antimalarial Resistance Network individual participant data meta-analysis

P Dahal, JA Simpson, S Abdulla, J Achan, I Adam, A Agarwal, R Allan, AR Anvikar, E Arinaitwe, EA Ashley, GR Awab, Q Bassat, A Björkman, F Bompart, S Borrmann, T Bousema, I Broek, H Bukirwa, VI Carrara, M Corsi Show all

Malaria Journal | BMC | Published : 2019

DOI: 10.1186/s12936-019-2837-4

Download PDF

Abstract

Background: Therapeutic efficacy studies in uncomplicated Plasmodium falciparum malaria are confounded by new infections, which constitute competing risk events since they can potentially preclude/pre-empt the detection of subsequent recrudescence of persistent, sub-microscopic primary infections. Methods: Antimalarial studies typically report the risk of recrudescence derived using the Kaplan-Meier (K-M) method, which considers new infections acquired during the follow-up period as censored. Cumulative Incidence Function (CIF) provides an alternative approach for handling new infections, which accounts for them as a competing risk event. The complement of the estimate derived using the K-M ..

View full abstract

University of Melbourne Researchers

Julie Simpson Author

Related Projects (1)

INTEGRATION OF BIOSTATISTICS AND MATHEMATICAL MODELLING TO IMPROVE THE CONTROL OF INFECTIOUS DISEASES

Improving the control of infectious diseases requires the evaluation of interventions that prevent disease at the population level and succe..

Grants

Awarded by Bill and Melinda Gates Foundation

Funding Acknowledgements

PD is funded by Tropical Network Fund, Nuffield Department of Clinical Medicine, University of Oxford. The WorldWide Antimalarial Resistance Network (PD, KS, RNP, GSH, and PJG) is funded by a Bill and Melinda Gates Foundation grant and the ExxonMobil Foundation. JAS is an Australian National Health and Medical Research Council Senior Research Fellow (1104975). RNP is a Wellcome Trust Senior Fellow in Clinical Science (200909). The funders did not participate in the study development, the writing of the paper, decision to publish, or preparation of the manuscript.